Anti-TNF-α Therapy for Extraintestinal Manifestations of Inflammatory Bowel Disease

Research output: Contribution to journalJournal articlepeer-review

The introduction of biological tumor necrosis factor (TNF)-α inhibitors has transformed the paradigm for the treatment of inflammatory bowel disease (IBD), i.e. Crohn's disease and ulcerative colitis. The specific TNF inhibitors currently approved for patients with IBD are infliximab, adalimumab and certolizumab pegol for Crohn's disease refractory to conventional treatment and infliximab, adalimumab, and golimumab for ulcerative colitis. Additionally, many patients with IBD have extraintestinal manifestations, and biological TNF inhibitors have also been shown to be of therapeutic benefit for these patients. The present chapter highlights these indications.

Original languageEnglish
Book seriesFrontiers of Gastrointestinal Research
Volume34
Pages (from-to)206-213
ISSN0302-0665
DOIs
Publication statusPublished - 2015

ID: 218706959